1. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis;Boy;J Invest Dermatol,2009
2. Treatment with Ruxolitinib, an orally bioavailable JAK1/2 inhibitor, prevents the onset of alopecia areata in C3H/HeJ mice. Immunology I: Adaptive Immunity Abstracts;Dai;J Invest Dermatol,2012
3. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550);Ghoreschi;J Immunol,2011
4. Reversal of longstanding alopecia areata in C3H/HeJ mice using topical JAK inhibitors. 7th World Congress for Hair Research Abstracts;Jabbari;J Invest Dermatol,2013
5. Targeting of JAK3 prevents onset of murine alopecia areata. Immunology I: Adaptive Immunity Abstracts;Jabbari;J Invest Dermatol,2012